Gottlieb: Subscription Reimbursement Could Curb Antibiotic Resistance

FDA Commissioner Scott Gottlieb said his agency is discussing with public and private payers the possibility of establishing a subscription-based reimbursement policy that offers an incentive for drug makers to develop new antibiotics while health care providers are pressed to cut down on use of those drugs. Gottlieb said FDA alone will not be able to fix the systemic problems behind the growth of antimicrobial resistance (AMR). He announced an extensive plan Friday (Sept. 14) that calls for: facilitating new...